# Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)

> **NCT03792516** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- Vulvar Dysplasia
- HPV-Related Vulvar Intraepithelial Neoplasia
- Preinvasive Vulvar Disease
- Vulva Intraepithelial Neoplasia
- Vulvar Diseases

## Interventions

- **DRUG:** artesunate ointment 40%

## Key facts

- **NCT ID:** NCT03792516
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2022-08-31
- **Final completion:** 2024-12-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792516, "Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT03792516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*